Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Founded in 2018, Quan Capital is a venture capital firm based in Shanghai, China, focusing on the life sciences sector. The firm specializes in identifying and nurturing innovative companies that are poised to make significant impacts in healthcare. Quan Capital emphasizes therapeutic biotech, enabling technologies, and precision medicine, leveraging its extensive global networks and local expertise to support the growth of its portfolio companies.
As of now, Quan Capital manages a portfolio of 11 companies and is actively involved in the company-building process. The firm is committed to addressing major healthcare problems through disruptive solutions, particularly in the context of the rapidly evolving healthcare landscape in China. Their investment strategy encompasses various stages, including pre-seed, seed, seed-plus, Series A, Series B, and growth equity, allowing them to engage with companies at different points in their development.
Notable milestones include successful exits such as ARMO Biosciences and dMed, showcasing their ability to identify and support high-potential companies. Quan Capital's team comprises seasoned investment professionals with a proven track record in the life sciences sector, further enhancing their capability to drive value creation across their portfolio.
Quan Capital invests in early and growth-stage life sciences companies globally, with a particular emphasis on China. Their investment strategy includes therapeutic biotech and pharma, enabling technologies, high-end specialty services, companion diagnostics, and precision medicine. The firm is particularly interested in companies developing innovative solutions in oncology, immunology, and rare diseases.
The firm seeks to discover, incubate, and grow next-generation life sciences companies that address critical healthcare challenges. They focus on breakthrough therapies and cutting-edge technologies within the evolving healthcare landscape. Quan Capital looks for founders with strong scientific backgrounds and a clear path to commercialization, particularly in complex areas such as clinical, regulatory, and manufacturing processes.
Investment checks are made across various stages, allowing flexibility in funding strategies. The firm’s geographic focus spans both global markets and specific attention to the Chinese healthcare system, where they leverage local insights to enhance portfolio company success.
Quan Capital's portfolio includes a diverse range of companies focused on innovative life sciences solutions:
Notable exits from their portfolio include ARMO Biosciences, an immuno-oncology company, and dMed, a specialty clinical development CRO focused on China.
Samantha Du: Founding Managing Director. She has a background in establishing Zai Lab and has extensive experience in the life sciences sector.
Marietta Wu: Managing Director. Marietta brings significant expertise in venture capital and life sciences investments.
Stella Xu: Managing Director. Stella has a strong track record in managing investments in biotech companies.
Rick Xu: Venture Partner. Rick has experience in various biotech ventures and contributes to strategic decision-making.
John Wong: Venture Partner. John focuses on identifying promising investment opportunities in the life sciences sector.
Harald Reinhart: Venture Partner. Harald has a background in biotech and supports portfolio companies in their growth strategies.
Peter Wirth: Senior Advisor. Peter provides strategic insights and guidance to the firm.
Angela Shen: Senior Advisor. Angela offers expertise in operational support and market entry strategies.
Yingying Yang: Partner. Yingying plays a key role in investment decisions and portfolio management.
Zhanghang Yan: Vice President. Zhanghang supports the investment team with analysis and due diligence.
Yiwei Gong: Associate. Yiwei assists in research and portfolio management activities.
Crystal Yin: Director, Finance. Crystal manages financial operations and reporting for the firm.
Stacy Sun: Senior Accountant. Stacy oversees accounting functions and financial compliance.
Lena Guo: Operation Manager. Lena manages operational processes and supports the investment team.
Cherry Jin: Executive Assistant. Cherry provides administrative support to the team.
To pitch Quan Capital, founders should send an email to info@quancapital.com with a detailed pitch deck. The deck should include information about the technology, market opportunity, competitive landscape, and team qualifications. Quan Capital prefers concise and clear presentations that highlight the startup's unique value proposition.
Response times may vary, but founders can expect feedback within a few weeks. Warm introductions are beneficial but not mandatory. The firm appreciates thorough preparation and a clear articulation of the startup's vision and strategy.
In April 2026, Quan Capital highlighted significant developments in its portfolio companies, including collaborations and financing rounds. Notably, Oricell Therapeutics closed over $110 million in pre-IPO financing, showcasing the firm's active engagement in supporting its portfolio.
Additionally, Avenzo Therapeutics announced a $60 million Series B financing in September 2025, with Quan Capital participating as an existing investor. This reflects the firm's ongoing commitment to backing innovative life sciences companies.
What are Quan Capital's investment criteria?
Quan Capital focuses on early and growth-stage life sciences companies, particularly in therapeutic biotech, enabling technologies, and precision medicine. They look for innovative solutions in oncology, immunology, and rare diseases.
How can I pitch to Quan Capital?
Founders can reach out via email at info@quancapital.com. A well-prepared pitch deck should include details on the technology, market opportunity, and team background.
What makes Quan Capital different from other VCs?
Quan Capital combines global biotech networks with local execution capabilities in China, providing unique insights and support for navigating the complexities of the Chinese healthcare market.
What is the geographic scope of Quan Capital's investments?
The firm invests globally, with a strong emphasis on the Chinese market, leveraging local expertise to enhance portfolio company success.
What is the typical check size for investments?
While specific check sizes are not disclosed, Quan Capital invests across various stages, including pre-seed, seed, Series A, and Series B, indicating flexibility in funding amounts.
What kind of post-investment support does Quan Capital provide?
Quan Capital offers hands-on support in strategy, operations, and development, leveraging its extensive networks in the biotech industry to facilitate cross-border collaboration and commercialization.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.